MOUNJARO 2.5 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 2.5 mg/.5mL

Tirzepatide works by enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner. It selectively binds to and activates both the GIP and GLP-1 receptors, which helps to lower fasting and postprandial glucose concentrations, decrease food intake, and reduce body weight in patients with type 2 diabetes mellitus.

The recommended starting dosage of MOUNJARO 2.5 mg/0.5mL is 2.5 mg injected subcutaneously once weekly. The dose can be increased in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg once weekly for adults and 10 mg once weekly for pediatric patients 10 years of age and older. The prescriber will determine the appropriate dose based on individual patient needs.

The safety of MOUNJARO 2.5 mg/0.5mL during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using this medication during pregnancy or while breastfeeding.

To order MOUNJARO 2.5 mg/0.5mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

MOUNJARO 2.5 mg/0.5mL is a dual GIP and GLP-1 receptor agonist, which distinguishes it from other type 2 diabetes medications that may only target one of these receptors. This dual action can provide additional benefits in glycemic control and weight management compared to single-receptor agonists.

MOUNJARO 2.5 mg/0.5mL should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). If needed, it can be stored at room temperature up to 86°F (30°C) for up to 21 days. It should be protected from light and not be frozen. Always follow the storage instructions provided in the product packaging.

MOUNJARO 2.5 mg/0.5mL is administered subcutaneously once weekly. It can be injected in the abdomen, thigh, or upper arm. The injection site should be rotated with each dose. The medication can be administered at any time of day, with or without meals.

The most serious risks to watch for with MOUNJARO 2.5 mg/0.5mL include acute pancreatitis, severe hypoglycemia when used with insulin secretagogues or insulin, hypersensitivity reactions, acute kidney injury due to volume depletion, and severe gastrointestinal adverse reactions. Patients should be monitored closely for these potential risks.

MOUNJARO 2.5 mg/0.5mL should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also not recommended for patients with severe gastroparesis. Always consult with a healthcare provider to determine if this medication is appropriate for you.